China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio – pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.
Financing Details and Future Plans
The Series A + financing raised a total of RMB 580 million (USD 84 million), valuing Hui Sheng Bio at RMB 5.58 billion (USD 808.83 million). Sihuan retains a 61.29% stake in Hui Sheng Bio. The proceeds from the financing will be used for product promotion, clinical studies, and supplementary working capital. This strategic funding aims to accelerate the development and commercialization of Hui Sheng Bio’s robust diabetes pipeline.
Focus on Diabetes and Pipeline Highlights
Hui Sheng Bio is focused on the diabetes market, with over 40 products in its pipeline. These include second – , third – , and fourth – generation insulins and analogs (such as basic, pre – mixed, and fast – acting products), as well as molecules targeting SGLT – 2 and GLP – 1 receptors. The comprehensive pipeline positions Hui Sheng Bio to address significant unmet medical needs in diabetes management and treatment.-Fineline Info & Tech
